| Species Reactivity | Human |
| Clone | Trebananib |
| Source/Isotype | Human Fc |
| Application | / |
| Specificity | Detects ANGPT2 |
| Gene | ANGPT2 |
| Other Names | AGPT2,ANG2,Angiopoietin-2 |
| Gene ID | 285 (Human) |
| Background | Trebananib (AMG 386) is a peptide body fusion protein that targets the binding of angiopoietin-1(ANG1) and angiopoietin-2(Ang2) to the Tie2 receptor to exert antitumor effects by inhibiting tumor angiogenesis. Its unique mechanism is different from traditional VEGF inhibitors (such as bevacizumab) , which can reduce serious side effects such as intestinal perforation and hypertension, but edema is the main adverse reaction. In the ovarian cancer phase III trial (Trinova-1) , the combination with paclitaxel prolonged median progression-free survival (PFS) to 7.2 months (vs. 5.4 months in the placebo group) , but overall survival (OS-RRB- was not significantly improved; As an innovative drug in the field of antiangiogenesis, Trebananib regulates the tumor microenvironment by blocking the ANG/Tie2 axis, providing new ideas for the treatment of multiple cancer species, and promoting the development of antiangiogenic drugs, however, it is necessary to further explore the combination of drugs, sequential treatment and subtype-specific application to break through the existing limitations. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | Trebananib |
| Source/Isotype | Human Fc |
| Application | / |
| Specificity | Detects ANGPT2 |
| Gene | ANGPT2 |
| Other Names | AGPT2,ANG2,Angiopoietin-2 |
| Gene ID | 285 (Human) |
| Background | Trebananib (AMG 386) is a peptide body fusion protein that targets the binding of angiopoietin-1(ANG1) and angiopoietin-2(Ang2) to the Tie2 receptor to exert antitumor effects by inhibiting tumor angiogenesis. Its unique mechanism is different from traditional VEGF inhibitors (such as bevacizumab) , which can reduce serious side effects such as intestinal perforation and hypertension, but edema is the main adverse reaction. In the ovarian cancer phase III trial (Trinova-1) , the combination with paclitaxel prolonged median progression-free survival (PFS) to 7.2 months (vs. 5.4 months in the placebo group) , but overall survival (OS-RRB- was not significantly improved; As an innovative drug in the field of antiangiogenesis, Trebananib regulates the tumor microenvironment by blocking the ANG/Tie2 axis, providing new ideas for the treatment of multiple cancer species, and promoting the development of antiangiogenic drugs, however, it is necessary to further explore the combination of drugs, sequential treatment and subtype-specific application to break through the existing limitations. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
